Randomised Phase 2 study of lapatinib and vinorelbine vs vinorelbine in patients with HER2 + metastatic breast cancer after lapatinib and trastuzumab treatment (KCSG BR11-16)

被引：0
|
作者：
Sung Hoon Sim
In Hae Park
Kyung Hae Jung
Sung-Bae Kim
Jin-Hee Ahn
Kyung-Hun Lee
Seock-Ah Im
Young-Hyuck Im
Yeon Hee Park
Joohyuk Sohn
Yu Jung Kim
Suee Lee
Hee-Jun Kim
Yee Soo Chae
Kyong Hwa Park
Byung-Ho Nam
Keun Seok Lee
Jungsil Ro
机构：
[1] National Cancer Center,Center for Breast Cancer, Research Institute
[2] University of Ulsan,Asan Medical Center
[3] College of Medicine,Seoul National University Hospital, Cancer Research Institute
[4] Seoul National University,Samsung Medical Center
[5] College of Medicine,Yonsei University, College of Medicine
[6] Sungkyunkwan University,Division of Hematology and Medical Oncology, Department of Internal medicine
[7] School of Medicine,Department of Internal medicine
[8] Yonsei Cancer Center,Department of Internal Medicine, Division of Oncology/Hematology
[9] Seoul National University Bundang Hospital,Biometric Research Branch, Division of Cancer Epidemiology and Prevention
[10] Dong-A University,undefined
[11] College of Medicine,undefined
[12] Chung-Ang University,undefined
[13] College of Medicine,undefined
[14] Kyungpook National University,undefined
[15] College of Medicine,undefined
[16] Korea University,undefined
[17] Research Institute & Hospital,undefined
[18] National Cancer Center,undefined
来源：
British Journal of Cancer | 2019年 / 121卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：985 / 990
页数：5
相关论文
共 50 条
  • [1] Randomised Phase 2 study of lapatinib and vinorelbine vs vinorelbine in patients with HER2+metastatic breast cancer after lapatinib and trastuzumab treatment (KCSG BR11-16)
    Sim, Sung Hoon
    Park, In Hae
    Jung, Kyung Hae
    Kim, Sung-Bae
    Ahn, Jin-Hee
    Lee, Kyung-Hun
    Im, Seock-Ah
    Im, Young-Hyuck
    Park, Yeon Hee
    Sohn, Joohyuk
    Kim, Yu Jung
    Lee, Suee
    Kim, Hee-Jun
    Chae, Yee Soo
    Park, Kyong Hwa
    Nam, Byung-Ho
    Lee, Keun Seok
    Ro, Jungsil
    [J]. BRITISH JOURNAL OF CANCER, 2019, 121 (12) : 985 - 990
  • [2] Randomized phase II study of lapatinib plus vinorelbine versus vinorelbine in patients with HER2 positive metastatic breast cancer progressed after lapatinib and trastuzumab treatment
    Sim, S. H.
    Park, I. H.
    Jung, K. H.
    Kim, S-B
    Ahn, J-H
    Lee, K-H
    Im, S-A
    Im, Y-H
    Park, Y. H.
    Sohn, J. H.
    Kim, Y. J.
    Lee, S.
    Kim, H-J
    Chae, Y. S.
    Park, K-H
    Nam, B-H
    Lee, K. S.
    Ro, J.
    [J]. CANCER RESEARCH, 2019, 79 (04)
  • [3] Phase I study of lapatinib plus vinorelbine in patients with locally advanced or metastatic breast cancer overexpressing HER2
    E Brain
    N Isambert
    F Dalenc
    V Diéras
    J Bonneterre
    K Rezai
    M Jimenez
    F Mefti-Lacheraf
    E Cottura
    P Tresca
    L Vanlemmens
    C Mahier-Aït Oukhatar
    F Lokiec
    P Fumoleau
    [J]. British Journal of Cancer, 2012, 106 : 673 - 677
  • [4] Phase I study of lapatinib plus vinorelbine in patients with locally advanced or metastatic breast cancer overexpressing HER2
    Brain, E.
    Isambert, N.
    Dalenc, F.
    Dieras, V.
    Bonneterre, J.
    Rezai, K.
    Jimenez, M.
    Mefti-Lacheraf, F.
    Cottura, E.
    Tresca, P.
    Vanlemmens, L.
    Oukhatar, C. Mahier-Ait
    Lokiec, F.
    Fumoleau, P.
    [J]. BRITISH JOURNAL OF CANCER, 2012, 106 (04) : 673 - 677
  • [5] A phase I/II study of the combination of lapatinib and oral vinorelbine in HER2 positive metastatic breast cancer
    Chen, T. W-W
    Yeh, D-C
    Chao, T-Y
    Lin, C-H
    Chow, L. W-C
    Hsieh, Y-Y
    Huang, S-M
    Cheng, A-L
    Huang, C-S
    Lu, Y-S
    [J]. CANCER RESEARCH, 2016, 76
  • [6] Trastuzumab and vinorelbine combination in the treatment of Her2 positive metastatic breast cancer.
    Bayo, J
    Mayordomo, JI
    Sanchez-Rovira, P
    Perez-Carrion, R
    Illaramendi, J
    Flores, EG
    Bueno, JMG
    Vazquez, MR
    Crespo, C
    Palomo, AG
    Huelva, HJRJ
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 67S - 67S
  • [7] A Phase I/II study of the combination of lapatinib and oral vinorelbine in HER2-positive metastatic breast cancer
    Chen, Tom Wei-Wu
    Yeh, Dah-Cherng
    Chao, Tsu-Yi
    Lin, Ching-Hung
    Chow, Louis Wing-Cheong
    Chang, Dwan-Ying
    Hsieh, Yao-Yu
    Huang, Shu-Min
    Cheng, Ann-Lii
    Lu, Yen-Shen
    [J]. JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2018, 48 (03) : 242 - 247
  • [8] EFFECTS OF TRASTUZUMAB AND LAPATINIB ON HER2 POSITIVE BREAST CANCER TREATMENT
    Jia, W.
    Wang, T. Z.
    [J]. JOURNAL OF BIOLOGICAL REGULATORS AND HOMEOSTATIC AGENTS, 2019, 33 (02): : 551 - 555
  • [9] Phase II study of lapatinib in combination with vinorelbine, as first or second-line therapy in women with HER2 overexpressing metastatic breast cancer
    Chew, Helen Kent
    Schwartzberg, Lee
    Badarinath, Suprith
    Rubin, Peter
    Shumaker, Grace
    Daugherty, James
    DeSilvio, Michelle
    Mahoney, Janine
    [J]. SPRINGERPLUS, 2014, 3
  • [10] Tolerability of the combination of lapatinib and trastuzumab in older patients with HER2 positive metastatic breast cancer
    O'Connor, Tracey
    Soto-Perez-de-Celis, Enrique
    Blanchard, Suzette
    Chapman, Andrew
    Kimmick, Gretchen
    Muss, Hyman
    Luu, Thehang
    Waisman, James R.
    Li, Daneng
    Mortimer, Joanne
    Yuan, Yuan
    Somlo, George
    Stewart, Daphne
    Katheria, Vani
    Levi, Abrahm
    Hurria, Arti
    [J]. CANCER RESEARCH, 2018, 78 (04)
12345